INTRODUCTION-There is limited understanding of relationships between genotype, phenotype and other conditions contributing to health in neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) identified through newborn screening.
INTRODUCTION
Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) is an autosomal recessive mitochondrial fatty acid oxidation disorder. A recent report on the birth prevalence of disorders detectable through newborn bloodspot screening noted an overall MCADD birth prevalence of 5.3 (4.1-6.7, 99% CI) per 100,000 births across a variety of racial/ethnic groups (1) . Impaired hepatic ketogenesis resulting in hypoketotic hypoglycemia, metabolic acidosis, liver disease, and lethargy can rapidly progress to coma and death when glycogen stores are depleted during catabolic physiological states (2) . Undiagnosed, morbidity and mortality are considerable, but when the diagnosis is known, MCADD can be successfully managed and outcomes improved (3) . Early detection of affected infants is important (4) . Thus, MCADD is a core condition on the U.S. Department of Health and Human Services Advisory Committee on Heritable Disorders in Newborns and Children's Recommended Uniform Screening Panel and newborn screening for this condition is done in all 50 U.S. states, the District of Colombia and Puerto Rico (5) (6) . Despite an acknowledgement that this condition can have a significant health impact in early life, limited understanding exists of the complex interplay between genotype, biochemical phenotype, and other conditions associated with health outcomes of neonates with MCADD.
Accumulation of the medium-chain acylcarnitine species is characteristic of MCADD, with octanoylcarnitine (C8) as the prominent blood marker (7) . Higher C8 values in blood spot newborn screening have been reported in association with homozygosity for the common c. 985A>G pathogenic gene variant (8) , or the presence of other severe pathogenic variants such as deletion, nonsense, or splice site mutations in the ACADM gene (9) . Higher blood spot C8 values have also been reported in MCADD affected neonates, particularly those homozygous for the c.985A>G mutation, whose blood spots were collected sooner after birth (10) . 
METHODS

DATA
The research protocol was approved by the Institutional Review Boards of the Inborn Errors of Metabolism Collaborative (IBEMC) partners and informed consent was documented in the Inborn Errors of Metabolism -Information System (IBEM-IS) for all enrolled MCADD subjects (11) (12) . The IBEMC data collection began in 2007 and is currently managed using REDCap electronic data capture tools hosted at the Michigan Public Health Institute (MPHI) (13) .
Data for this study were extracted from the IBEM-IS on August 7, 2015. The inclusion criteria for this study were subjects having: 1) consented for data-sharing, 2) assignment of the condition MCADD, 3) abnormal newborn screening result, and 4) a first newborn screen C8 value. Newborn screen MCADD-related acylcarnitine values other than C8 were not included in this study due to insufficient data collection on those values in the IBEM-IS. Blood spot collection timing was unavailable for most subjects.
VARIABLES
The IBEM-IS defines the neonatal period as the first 28 days of life. (35) , and D) empty or indecipherable entries in the allele data fields, as data are entered as free text. The dataset contained eight combinations of two alleles: AA (n=69), AB (n=18), BB (n=1), AC (n=49), AD (n=26), CC (n=12), CD (n=2), and DD (n=44). The BB group contained too few cases to compute stable statistics and was excluded from genotype analysis. The AD, CD, and DD groups were also excluded from analysis due to the lack of usable genotype information. The remaining four genotype categories were further collapsed into two categories for selected additional analyses as follows: 1) AA and AB, and 2) AC and CC.
STATISTICAL ANALYSES
The Mann-Whitney U test was used to assess differences in C8 values between each pair of groups, defined by: low birth weight or not, breastfed only or not, presence or absence of neonatal triggers, presence or absence of neonatal symptoms, presence or absence of neonatal abnormal labs, and the two collapsed genotype categories. The Kruskal-Wallis test was used to compare C8 values among the four genotype categories. Correlations between C8, birth weight and age at first visit were tested using the Spearman correlation test. Chisquare tests were used to test the associations between categorical variables.
To further examine whether the strength of the relationship between C8 and age at first visit differs between each pair of subgroups defined by, presence or absence of neonatal triggers, presence or absence of neonatal symptoms, and presence or absence of neonatal abnormal labs, we constructed three generalized linear models (negative binomial with log link function). In each model, age at first visit was the dependent variable, C8 and one of the above three binary variables, along with the interaction term, were the independent variables.
Logistic regression with neonatal symptoms as the binary outcome variable, and the collapsed genotype category, C8, and gender as predictors, was conducted to determine whether these variables predict the likelihood of developing neonatal symptoms.
All statistical significance tests were two-sided. Bonferroni correction was used to adjust for multiple comparisons to keep the overall significance level at α=0.05. All the statistical analyses were conducted in IBM SPSS Statistics for Windows, Version 23.0.
RESULTS
A total of 337 consented subjects were assigned the condition MCADD, 285 (85%) of whom had abnormal newborn screening. Of the 285 subjects, 223 had a first newborn screen C8 value documented in the IBEM-IS. Two subjects with first newborn screen C8 values presumed to be erroneously recorded (2406 umol/L and 1738 umol/L) were excluded. The remaining 221 subjects, all identified in the IBEM-IS as alive at the time of data extraction, constituted the dataset for this study.
Age of subjects at IBEMC enrollment ranged from infancy to 10 years (n=218). Average reported birth weight was 3.35 kg (n=213, Std. Dev.=0.53). Subjects' first newborn screen C8 value averaged 11.2 umol/L (median=8.6, range 0.36-43.91, Std. Dev.=10.12). MCADD diagnostic testing was documented to be done for the majority of subjects in this cohort (Table 1) .
Eligibility for enrollment in the IBEMC is dependent upon the individual having been given a diagnosis of an inborn error of metabolism, in this case, MCADD. Diagnostic methods and results were documented in the IBEM-IS for the majority of subjects with MCADD included in this study ( Table 2 ).
The majority of subjects had at least one clinical biochemical diagnostic laboratory test abnormality and/or two ACADM allele findings recorded in the IBEM-IS (N=189, 86%).
Among the five subjects with normal biochemical diagnostic testing recorded, three had two ACADM allele findings, with genotype categories AA, CC, and CC. The two CC subjects had normal plasma acylcarnitine profiles, the AA subject had normal urine organic acids, and additional biochemical diagnostic testing results were not recorded for these three subjects. The remaining two subjects had one allele finding, both with normal urine organic acids and without other biochemical diagnostic testing results recorded.
Subjects' average age at notification of the first abnormal newborn screen to a primary care or metabolic provider was 7.45 days (n=191, Std. Dev.=19.44). Average age since birth to initiation of intervention for MCADD was 8.11 days (n=197, Std. Dev.=19.41). Subjects averaged 16.77 days of age at the time of the first subspecialist visit (n=202, Std. Dev.=22.27).
The types and frequencies of select neonatal clinical characteristics and laboratory abnormalities in our dataset are summarized in Table 3 .
C8 values and age at first visit were negatively correlated (p = 0.001, Spearman's rho = −0.227) indicating subjects seen by subspecialists sooner had higher C8 levels. Generalized linear regression results confirmed the negative correlation; for every one unit increase in C8, age at first visit decreased by 2% (p < 0.001). While the correlation was stronger (more negative) in subjects who had neonatal symptoms or neonatal abnormal labs than for subjects who did not, the difference in the magnitude of the correlation was not statistically significant. C8 values significantly differed among the four genotype categories (p<0.001). Post hoc pairwise comparisons showed C8 values significantly higher in the AA genotype group than in the AC (adjusted p<0.001) and CC (adjusted p=0.001) groups; and C8 values significantly higher in the AB genotype group than in the AC group (adjusted p=0.046). Although the data suggested a difference in C8 values between the AB genotype and the CC genotype groups, the test failed to reach statistical significance (adjusted p=0.144), which may be due to low power. C8 values were significantly higher in the AA&AB group than in the AC&CC group (p<0.001). Figure 1 shows the mean, median, and rank of C8 value for the fourcategory and two-category genotype variables.
For subjects with recorded and decipherable ACADM allele findings in the IBEM-IS, the c.
985A>G mutation was most frequently appearing. The c.199T>C allele was the next most frequently appearing, with twelve subjects compound heterozygous for this allele and the c. 985A>G mutation, and two subjects heterozygous for this allele and two other C type alleles. Subjects with the c.985A>G/c.199T>C genotype had first newborn screen C8 values ranging from 1.28-5.43 umol/L) and either no or unknown triggers, symptoms or abnormal labs in the first 28 days of life. The other two subjects with the c.199T>C/other C type genotype had first newborn screen C8 values of ≤0.6 umol/L, and had no triggers, symptoms or abnormal labs in the first 28 days of life. 
CONCLUSIONS
This collaborative study is the first in the United States to describe health associations of a large cohort of newborn-screened neonates with MCADD. The IBEM-IS platform was designed to allow examination of complex associations between newborn screening results, clinical conditions and laboratory findings of individuals with inborn errors of metabolism. The IBEM-IS data increases our understanding of interactions with public health and clinical systems related to the notification and follow-up of abnormal newborn screening results for children with rare inborn errors of metabolism. The opportunity to examine a large cohort of newborn screened individuals with MCADD expands understanding of factors associated with their health in the first 28 days of life.
In 2014, the Society of Inherited Metabolic Disorders identified MCADD as one of several critical conditions requiring immediate notification of the health care provider upon ascertainment of an abnormal newborn screening result (36) . Recently, the Advisory Committee on Heritable Disorders in Newborns and Children recommended that presumptive positive screening results for time-critical conditions be immediately reported to the child's health care provider and by no later than 5 days of life (37) . Our subjects had a longer documented mean age (7.45 days) at the time of newborn screen result notification indicating that improvement in timely notification must remain a priority to minimize risks of symptom initiation in these vulnerable newborns. Initiation of MCADD intervention occurred at a mean age of 8 days in our cohort. The close proximity in time of notification and intervention reflects the priority of clinicians to intervene in the care of newborns with possible MCADD as soon as possible.
In an attempt to determine if poor initiation of breast-feeding might be a risk factor for neonates with this condition, we specifically queried whether the diet of the neonates was associated with C8 values. Despite the failure to observe an association between high C8 values and exclusive breast-feeding in this data analysis, neonates who are exclusively breast-fed and in whom initiation of feeding is problematic may well be at additional risk for decompensation. Our observations cannot rule out poor breastfeeding initiation as a risk factor without additional information about this specific issue.
C8 values >0.3 umol/L along with additional results of MCADD-related ratios have been considered by some as indicative of MCADD by neonatal screening (20) (38) . A worldwide collaborative project looking at the clinical validation of the cutoff target range of C8 in tandem mass spectrometry newborn screening describes disorder ranges for acylcarnitines and related ratios in MCADD, creating a tool for assessing screening results (39) . Although all subjects in our cohort had a first newborn screen C8 value ≥0.36 umol/L, data available did not uniformly include additional newborn screening acylcarnitine values or ratios, preventing inclusion in our data analysis. The significant associations we found between the first newborn screen C8 value and low birth weight, symptoms, and clinical lab abnormalities for neonates with MCADD highlight the importance of providing quantitative screening result data to clinicians caring for children with abnormal newborn screen results for MCADD. Clinicians receiving such results should view very high C8 values as a signal for increased concern for symptomatic presentation of the condition.
Overrepresentation of infants with flagged newborn screening acylcarnitine values among infants in neonatal intensive care or with very low birth weight has been reported (10). Distribution of blood spot C8 concentrations did not vary greatly by birth weight in another study (40) . In our study, neonates with MCADD in the low birth weight (<=2.5 kg) group had significantly lower C8 values. Although some of our low birth weight subjects had neonatal triggers, most had neither neonatal symptoms nor neonatal abnormal labs, and 7 out of 13 were homozygous for the c.985A>G ACADM mutation. These findings suggest that low birth weight itself may be a factor associated with lower newborn screen C8 values than might otherwise be expected given risk factors such as a deleterious genotype. The relative lower C8 values in this group may be due to these babies with low birth weight already receiving medical care with adequate prevention of fasting to prevent MCADD-associated complications causing elevations of C8. Data collection regarding the timing of first newborn screen sampling was a relatively recent addition to the IBEM-IS. Therefore, data on age at first newborn screen bloodspot collection was unavailable for most of our subjects. This is an important limitation to the conclusions of our study, given the findings of others regarding the relationship of C8 values and age at sample timing for infants with MCADD, as previously noted (10).
Our findings support the work of others demonstrating significant associations between higher C8 newborn screen values and homozygosity for the c.985A>G mutation as well as higher C8 newborn screen values in the presence of other severe ACADM mutations.
Conservative categorization of B genotype alleles may have influenced our results. Some C genotype alleles may be more deleterious than currently categorized, solely supported by our literature search, a strategy chosen to minimize the risk that our conclusions overemphasize the association between deleterious mutations and increasing C8 values.
Although this study includes information about a very large number of children with MCADD, there are important limitations in considering our conclusions. This cohort does not represent the full denominator of newborn-screened children diagnosed with MCADD in the catchment area of the participating IBEMC centers. Study limitations include the potential for selection bias in subject enrollment. We also accepted the premise that all subjects assigned the condition MCADD in the IBEM-IS are truly affected, and most but not all subjects in this study had IBEM-IS documentation of at least one biochemical diagnostic testing abnormality and/or two ACADM allele findings. While the IBEM-IS does not mandate documentation of the rationale for individual diagnostic testing decisions and practices, we note that of the 10% of subjects with ACADM molecular testing recorded as "not done" at the time of data extraction, all are minors and all had MCADD biochemical diagnostic testing performed. Over half of them had at least one biochemical diagnostic testing abnormality recorded, and the remainder of those subjects had wide ranging (0. Table 2 MCADD diagnostic methods and results 
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